SIDIPREV™
Inflammatory Bowel Diseases (Crohn's Disease, Ulcerative Colitis) - Maintenance of Remission
Key Facts
About LPOXY Therapeutics
LPOXY Therapeutics is a private, clinical-stage biotech pioneering a novel, non-antibiotic approach to preventing C. difficile infections (CDI) by modulating the gut microenvironment. Its core technology, SIDIPREV™ (LP-102), is an oral capsule that gently increases oxygen tension in the colon, creating an environment hostile to C. difficile growth while sparing the beneficial microbiota. With a $28M Series A financing led by 5 Horizons Ventures, the company is preparing for a pivotal clinical trial (STOP-Cdiff) in high-risk patients, addressing a critical unmet need classified as an 'Urgent' public health threat by the CDC. The platform also holds potential for inflammatory bowel disease.
View full company profile